Literature DB >> 16971115

What is the significance of pT0 at cystectomy?

Matthew Hotston1, Suril Patel, Muhammed Sohail, Rajendra A Persad.   

Abstract

The current treatment for muscle invasive bladder cancer is radical cystectomy. However, this approach leads to significant changes in the patient's quality of life, as well as potential treatment failure. And so, with the introduction of alternative and neoadjuvant therapies available, the presence of pT0 tumour at cystectomy confers a number of issues. The variability in numbers of pT0 tumours at cystectomy highlights the importance of adequate clinical staging, as well as the increasing successful use of neoadjuvant chemotherapy. Although current literature is limited, patients with prior clinical stage of muscle-invasive but node-negative disease are likely to demonstrate the most improvement in survivability if they subsequently develop pT0 at cystectomy. This review also highlights the importance of response to chemotherapy as an indicator of subsequent prognosis. With increasing numbers of pT0 tumours seen at radical cystectomy, it is suggested that more conservative measures, such as re-staging following neoadjuvant chemotherapy and even 'selective bladder preservation' treatment, may be the future for the management of muscle invasive bladder cancer.

Entities:  

Mesh:

Year:  2006        PMID: 16971115     DOI: 10.1016/j.suronc.2006.07.005

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

1.  Downstaging to non-invasive urothelial carcinoma is associated with improved outcome following radical cystectomy for patients with cT2 disease.

Authors:  Matthew K Tollefson; Stephen A Boorjian; Sara A Farmer; Igor Frank
Journal:  World J Urol       Date:  2012-03-25       Impact factor: 4.226

2.  Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy.

Authors:  Severin Rodler; Alexander Buchner; Lennert Eismann; Gerald Bastian Schulz; Julian Marcon; Stephan Ledderose; Boris Schlenker; Christian G Stief; Alexander Karl; Jan-Friedrich Jokisch
Journal:  Res Rep Urol       Date:  2022-08-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.